Integra Lifesciences Holdings (IART) Long-Term Debt Issuances (2010 - 2026)

Integra Lifesciences Holdings' Long-Term Debt Issuances history runs 16 years deep, the most recent figure standing at $44.5 million for Q1 2026.

• In Q1 2026, Long-Term Debt Issuances fell 18.2% year-over-year to $44.5 million; the TTM figure through Mar 2026 stood at $710.8 million (up 317.14% YoY), while the FY2025 annual figure was $720.7 million, up 48.14% from the prior year.
• Long-Term Debt Issuances came in at $44.5 million for Q1 2026 at Integra Lifesciences Holdings, down from $49.7 million in the prior quarter.
• In the past five years, Long-Term Debt Issuances ranged from a high of $603.7 million in Q3 2025 to a low of $5.0 million in Q2 2023.
• A 5-year average of $85.7 million and a median of $21.8 million in 2024 frame the typical range for Long-Term Debt Issuances.
• Across the five-year window, Long-Term Debt Issuances surged 3532.35% in 2024 and tumbled 85.32% in 2025, its largest moves.
• Integra Lifesciences Holdings' Long-Term Debt Issuances stood at $6.5 million in 2022, then soared by 180.0% to $18.2 million in 2023, then soared by 94.51% to $35.4 million in 2024, then soared by 40.4% to $49.7 million in 2025, then decreased by 10.46% to $44.5 million in 2026.
• According to Business Quant data, Long-Term Debt Issuances over the past three periods registered $44.5 million, $49.7 million, and $603.7 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison